BURLINGTON, Mass., May 20, 2026 — VentiraDx today announced that the company successfully participated in the 2026 American Urological Association (AUA) Annual Meeting, held May 15–18, 2026, in Washington, D.C. During the meeting, the VentiraDx team engaged in in-depth discussions with numerous urologists and uro-oncology specialists, gaining direct clinical insight that has further validated the commercial potential of TAGMeTM for urothelial carcinoma recurrence monitoring.
Throughout the conference, VentiraDx representatives met one-on-one with practicing urologists and uro-oncologists across the United States. These conversations consistently highlighted a significant unmet clinical need for non-invasive, reliable surveillance tools following treatment for urothelial carcinoma. Clinicians expressed strong interest in a urine-based assay that could reduce the burden of invasive cystoscopy while maintaining sensitivity for detecting early recurrence. The feedback from AUA 2026 has provided VentiraDx with concrete, field-level validation of the clinical use case TAGMeTM is designed to address.
Building on this clinical momentum, VentiraDx is now actively preparing for the commercial launch of TAGMeTM. The company is advancing its laboratory operations, refining its clinical positioning based on physician feedback received at AUA 2026, and establishing pathways for CLIA-certified laboratory partners to begin evaluation and LDT deployment. VentiraDx anticipates initiating controlled commercial availability in the near term.
“The conversations we had at AUA 2026 were genuinely transformative for our commercialization strategy,” said a spokesperson at VentiraDx. “Urologists told us directly that they need a tool like TAGMeTM — something that gives them a non-invasive, objective signal for recurrence without waiting for symptoms to progress. That clinical conviction, heard from physicians across the country, gives our team tremendous confidence as we move into launch. We return from Washington more committed than ever to bringing TAGMeTM to patients.”
VentiraDx will continue to engage with urologists and laboratory partners identified through AUA 2026 as it finalizes its launch preparation. Institutions and physicians interested in early access, clinical collaboration, or LDT evaluation are encouraged to contact the company directly.
For more information or to schedule a consultation, please contact:
Dr. Matthew Lei
Email: info@VentiraDx.com
Phone: (781) 230-6883
Website: www.ventiradx.com
About TAGMeTM
TAGMeTM is a urine-based DNA methylation assay developed for surveillance and monitoring of urothelial carcinoma recurrence. The assay is intended to support non-invasive longitudinal follow-up using methylation-based detection technology.
Regulatory Notice
TAGMeTM has received FDA Breakthrough Device Designation, which does not mean FDA clearance or approval. TAGMeTM is not FDA-cleared.